Nasdaq Stocks
Dish Network Stock Set For A 25% Gain?
Why Wheaton Precious Metals Stock Looks Undervalued Despite 100% Move
Time To Exit F5 Networks Stock?
Despite A 4x Rise, Editas Medicine May Continue To Trend Higher
Is Twitter's Stock Move Overdone?
Diodes Incorporated Stock To Return To Early 2020 Levels?
MasterCraft Is Going Digital For Its Dynamic Boat Show Season
MasterCraft Boat Holdings has launched a digital platform for its dynamic boat show season to engage digitally with its customers and dealer partners during the coronavirus pandemic.
MasterCraft’s (MCFT) digital platform, called the MasterCraft Experience Digital Boat Show, will provide a 360-degree experience showcasing new content. The show includes MasterCraft's headquarters videos and videos of its exclusive model walkthroughs. It will also detail the MasterCraft brand and its 2021 innovations to facilitate the boat-buying process.
The recreational powerboats manufacturer said that, “The MasterCraft Experience Digital Boat Show will introduce the newest innovations onboard MasterCraft’s model year 2021 NXT, XT, X, XStar and ProStar models and give visitors everything they need to experience the MasterCraft difference from anywhere at any time.” Further, the digital boat show will be free of cost for its customers and can be accessed any time and on any device on its website. (See MCFT stock analysis on TipRanks)
Back on Nov. 11, MasterCraft reported upbeat 1Q results. Its adjusted earnings of $0.58 per share grew 7.4% year-over-year and beat the Street's estimates of $0.33 per share. Its 1Q revenues of $103.7 million declined 5.5% year-over-year but exceeded analysts' expectations of about $96.2 million.
On Jan. 12, B. Riley Securities analyst Eric Wold raised the stock’s price target to $36 (33.1% upside potential) from $34 and maintained a Buy rating on the stock.
In a note to investors, Wold said, “With new boat registrations surging after the initial COVID-19 economic shutdowns (with average Y/Y monthly gains of 31% between June and November), typical new boat replacement cycles disrupted, channel inventory levels remaining depleted and dealer order books extending out for at least a year, we expect the extended selling season to drive better-than-expected production and shipment levels.”
From the rest of the Street, the stock scores a cautiously optimistic outlook with the analyst consensus of a Moderate Buy. The average analyst price target of $29 implies upside potential of about 7.3% to current levels. Shares have gained about 79% in one year.
Furthermore, TipRanks data shows that financial bloggers have a bullish call on the stock.
Related News:
China’s Tencent Music To Snap Up Lazy Audio For $417M; Street Is Bullish
Vail Resorts Sees Lower Ski Traffic in North America
XPeng To Roll Out Autonomous Driving Feature For Highways
POLL-BOJ's policy review may make ETF buying more flexible
POLL-Japan firms see capex rebound in FY2021 despite COVID hit
Is Smith & Wesson Brands, Inc. (SWBI) Stock Undervalued Right Now? (Revised)
Making A List Of Tech Stocks To Buy In January? 3 Names To Watch
Tesla Stock is Expensive, Here are Three Alternatives
3 Biotech Stocks To Watch This Week
Quest Diagnostics Wins Covid-19 Contract With US Health Agency
Quest Diagnostics has inked an agreement with the US Centers for Disease Control and Prevention (CDC) to provide genomic sequencing to identify new mutations and patterns of transmission of SARS-CoV-2, the virus that causes COVID-19.
Quest (DGX) didn’t disclose the financial terms of the collaboration. As part of the agreement, the diagnostics company will help CDC in conducting a large-scale longitudinal genomic survey of the SARS-CoV-2 virus using a random set of samples collected from its labs across the US. Quest will conduct the sequencing from its advanced diagnostics laboratory in San Juan Capistrano, California.
The collaboration comes as highly transmissible variants of the SARS-CoV-2 virus first discovered in the UK and South Africa have been identified in the US.
“Public and private collaboration is essential to mobilizing an effective response to COVID-19," said Quest Chief Medical Officer Jay G. Wohlgemuth. "Quest has the expertise in genomics and infectious diseases, as well as extensive COVID-19 testing data and access to patient samples. Our program will complement and extend the efforts of the CDC to discover and track new virus mutations and thereby improve public health response to the pandemic."
The CDC's survey aims to provide baseline information for national and state-level surveillance, help define changes in transmission, identify new variants of the virus, and improve the public health response to the virus.
Quest shares have gained 16% over the past year and looking ahead, the average analyst price target of $137.83 implies 11% upside potential in the coming 12 months.
Last month, Morgan Stanley analyst Ricky Goldwasser downgraded the stock to Hold from Buy and slashed the price target to $130 from $146.
Goldwasser expects earnings to decline in 2022 and as a result the analyst believes the stock is bound to underperform. For 2021 though, Street estimates are too low as the market is underestimating the near-term benefit from PCR testing, according to Goldwasser.
The rest of the Street is cautiously optimistic outlook on the stock. The Moderate Buy consensus is based on 5 Buys versus 3 Holds. (See Quest Diagnostics stock analysis on TipRanks).
Related News:
Acacia Pops 31% After Cisco Sweetens Buyout Offer To $4.5B
Beyond Meat Soars 14% On Taco Bell Partnership
Google, Nokia Partner To Develop Cloud-Based 5G Network